# Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease

> **NCT05854641** · PHASE4 · RECRUITING · sponsor: **Cell Biopeutics Resources Sdn Bhd** · enrollment: 10 (estimated)

## Conditions studied

- Critical Limb Ischemia
- Peripheral Arterial Disease

## Interventions

- **BIOLOGICAL:** Stempeucel®

## Key facts

- **NCT ID:** NCT05854641
- **Lead sponsor:** Cell Biopeutics Resources Sdn Bhd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05854641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05854641, "Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05854641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*